Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera
Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera
复制标题
DOI：
10.1038/s41591-021-01270-4
复制
发表时间：
2021-02-08
期刊：
影响因子：
82.9
通讯作者：
Shi, Pei-Yong
中科院分区：
文献类型：
--
作者：
Xie, Xuping;Liu, Yang;Shi, Pei-Yong
我们设计了三种严重急性呼吸综合征冠状病毒2（SARS-CoV-2），其中包含来自新出现的英国（UK）和南非（SA）变体的关键刺突突变：来自UK和SA的N501 Y;来自UK的69/70-缺失+N501 Y + D 614 G;以及来自SA的E484 K + N501 Y + D 614 G。20份BTN 162 b2疫苗引发的人血清针对三种突变病毒的中和几何平均滴度（GMT）是针对亲本病毒的GMT的0.81- 1.46倍，表明这些突变对两种BNT 162 b2疫苗引起的血清中和作用的影响很小。2种病毒在全球流行的令人担忧的变异体中含有刺突突变。
We engineered three severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viruses containing key spike mutations from the newly emerged United Kingdom (UK) and South African (SA) variants: N501Y from UK and SA; 69/70-deletion + N501Y + D614G from UK; and E484K + N501Y + D614G from SA. Neutralization geometric mean titers (GMTs) of 20 BTN162b2 vaccine-elicited human sera against the three mutant viruses were 0.81- to 1.46-fold of the GMTs against parental virus, indicating small effects of these mutations on neutralization by sera elicited by two BNT162b2 doses.Human sera from recipients of the BNT162b2 vaccine can neutralize SARS-CoV-2 viruses containing spike mutations present in globally circulating variants of concern.